[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
We regularly engage a conversation with the scientific community to share our knowledge.
This fall, we invite you to attend 3 webinars, explore with us the topic of Radiopharmaceutics, COVID-19 and Microbiome.
Ivan Gladwyn-Ng (Taconic), Sylvie Maubant (Oncodesign)
7th December 2021
Even if the causality is not always established, a microbial imbalance or dysbiosis are increasingly linked to several diseases including gastrointestinal and dermal diseases, metabolic disorders, CNS pathologies and cancer. Furthermore, the microbiome has been shown to influence the efficacy of immunotherapy and chemotherapeutic agents or to metabolize drugs. Based on preclinical and clinical studies, different strategies (e.g. fecal material, defined consortium, single strain) are adopted to modulate the composition of microbiome and exploit its immunogenicity to treat diseases in first line or to circumvent primary resistance to standard of care.
SOLO Microbiome help you understand and assess the role of the microbiome in drug discovery.
Meddy El Alaoui (Covalab), Frederic Boschetti (CheMatech), Andreas Kluge (ABX-CRO), Cyril Berthet (Oncodesign)
5th November 2021
Preclinical and clinical evaluation of radiopharmaceuticals can be sometimes seen as straightforward compared to non-radioactive molecules as the injected doses are often below toxic doses.
However, the development of theranostics requires highly specific expertise and strong collaboration between preclinical and clinical development. The discovery and development process require multiple and highly specialized skills, the combination of which rather nonexistent in a single structure, even more in the specialized field of radiopharmaceuticals.
The DRIVE™-Molecular RadioTherapy (MRT) offer is based on the complementary knowledge and know-how of each partner Covalab, CheMatech, ABX-CRO and Oncodesign, representing an experienced and innovative network in nuclear medicine.
Roger Le Grand (IDMIT/CEA), Nicolas Legrand (Oncodesign)
16th November 2021
Preclinical validation of an extended portfolio of prophylactic & therapeutic options against SARS-CoV-2-induced pathologies remains a major challenge for the scientific & medical community. In this context, the high value of several animal models of SARS-CoV-2 infection has been demonstrated to screen a variety of products such as vaccines, biologics or small molecules (repurposed drugs and new chemical entities). Still, choosing the right animal model might be challenging, based on various mode of actions and/or timing of action of the tested molecules.
In this webinar, our guest presenters will discuss several case studies to illustrate the features of rodent (golden Syrian hamster, human AC2-expressing mice) and nonhuman primate (NHP) models, which provide different pathology settings (moderate vs. severe COVID-19). These examples will help the attendees in their decision process regarding valid COVID-19 model selection.